Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AL6528 is a small molecule compound belonging to the sulfanilide class of organic compounds. It is characterized chemically as a thienothiazine sulfonamide derivative. While it has been studied as a discovery agent and drug candidate in preclinical research settings and included in chemical probe databases for its potential biological activity, there are no approved therapeutic indications or advanced clinical development programs reported for this compound. Its mechanism of action is presumed to involve inhibition of carbonic anhydrase enzymes based on structural similarity to other sulfonamides and related literature references[1][9][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AL6528.